000284094 001__ 284094
000284094 005__ 20260126111834.0
000284094 0247_ $$2doi$$a10.1016/j.ejphar.2015.11.034
000284094 0247_ $$2ISSN$$a0014-2999
000284094 0247_ $$2ISSN$$a1879-0712
000284094 037__ $$aDZNE-2026-00102
000284094 041__ $$aEnglish
000284094 082__ $$a610
000284094 1001_ $$aMatsui, Tamires C.$$b0
000284094 245__ $$aNicorandil inhibits neutrophil recruitment in carrageenan-induced experimental pleurisy in mice
000284094 260__ $$aNew York, NY [u.a.]$$bElsevier$$c2015
000284094 3367_ $$2DRIVER$$aarticle
000284094 3367_ $$2DataCite$$aOutput Types/Journal article
000284094 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1769422663_1864
000284094 3367_ $$2BibTeX$$aARTICLE
000284094 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000284094 3367_ $$00$$2EndNote$$aJournal Article
000284094 520__ $$aNicorandil is a drug characterized by the coupling of a nitric oxide (NO) donor to nicotinamide. We have previously demonstrated that nicotinamide exhibits activity in different models of pain and inflammation. Now, we investigated the effects induced by per os (p.o.) administration of nicorandil (25, 50 or 100mg/Kg) on neutrophil recruitment in a carrageenan-induced model of pleurisy in mice. Effects induced by nicorandil (100mg/kg) were compared with those induced by equimolar doses of nicotinamide (58mg/kg) and N-(2-hydroxyethyl)-nicotinamide (NHN; 79mg/kg). We also investigated whether effects on the production of inflammatory mediators play a role in the activity of nicorandil. P.o. nicorandil, 0.5h before and 1h after the i.pl. injection of carrageenan, reduced neutrophil recruitment. However, equimolar doses of nicotinamide or NHN failed to induce such effect. Single treatment (previous or late) with nicorandil (100mg/Kg, p.o.) also reduced neutrophils recruitment, although to a lesser extent when compared to the double treatment. Nicorandil reduced the concentrations of interleukin-1β, CXCL-1 and prostaglandin E2 in the pleural exudate. Concluding, we demonstrated the activity of nicorandil in a model of pleurisy induced by carrageenan. This activity was characterized by reduction of the neutrophil accumulation and inhibition of production of inflammatory mediators. The effects induced by nicorandil on the leukocytes recruitment and production of inflammatory mediators contribute to a better understanding of its clinical benefits and indicate that these benefits may be due to its vasodilating and anti-inflammatory activities.
000284094 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000284094 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000284094 650_7 $$2Other$$aCytokines
000284094 650_7 $$2Other$$aInflammation
000284094 650_7 $$2Other$$aNeutrophils
000284094 650_7 $$2Other$$aNicorandil
000284094 650_7 $$2Other$$aNicotinamide
000284094 650_7 $$2Other$$aProstaglandin E(2)
000284094 650_7 $$2NLM Chemicals$$aAnti-Inflammatory Agents
000284094 650_7 $$2NLM Chemicals$$aCytokines
000284094 650_7 $$2NLM Chemicals$$aEicosanoids
000284094 650_7 $$0260456HAM0$$2NLM Chemicals$$aNicorandil
000284094 650_7 $$09000-07-1$$2NLM Chemicals$$aCarrageenan
000284094 650_2 $$2MeSH$$aAnimals
000284094 650_2 $$2MeSH$$aAnti-Inflammatory Agents: pharmacology
000284094 650_2 $$2MeSH$$aCarrageenan: adverse effects
000284094 650_2 $$2MeSH$$aCytokines: biosynthesis
000284094 650_2 $$2MeSH$$aEicosanoids: biosynthesis
000284094 650_2 $$2MeSH$$aFemale
000284094 650_2 $$2MeSH$$aLeukocytes: drug effects
000284094 650_2 $$2MeSH$$aLeukocytes: immunology
000284094 650_2 $$2MeSH$$aLeukocytes: metabolism
000284094 650_2 $$2MeSH$$aMice
000284094 650_2 $$2MeSH$$aNeutrophil Infiltration: drug effects
000284094 650_2 $$2MeSH$$aNicorandil: pharmacology
000284094 650_2 $$2MeSH$$aNicorandil: therapeutic use
000284094 650_2 $$2MeSH$$aPleurisy: chemically induced
000284094 650_2 $$2MeSH$$aPleurisy: drug therapy
000284094 650_2 $$2MeSH$$aPleurisy: immunology
000284094 650_2 $$2MeSH$$aPleurisy: metabolism
000284094 7001_ $$aCoura, Giovanna M. E.$$b1
000284094 7001_ $$aMelo, Ivo S. F.$$b2
000284094 7001_ $$aBatista, Carla R. A.$$b3
000284094 7001_ $$aAugusto, Paulo Sérgio A.$$b4
000284094 7001_ $$aGodin, Adriana M.$$b5
000284094 7001_ $$aAraújo, Débora P.$$b6
000284094 7001_ $$aCésar, Isabela C.$$b7
000284094 7001_ $$0P:(DE-2719)9001782$$aSecchim Ribeiro, Lucas$$b8$$udzne
000284094 7001_ $$aSouza, Danielle G.$$b9
000284094 7001_ $$aKlein, André$$b10
000284094 7001_ $$ade Fátima, Ângelo$$b11
000284094 7001_ $$aMachado, Renes R.$$b12
000284094 7001_ $$aCoelho, Márcio M.$$b13
000284094 773__ $$0PERI:(DE-600)1483526-5$$a10.1016/j.ejphar.2015.11.034$$gVol. 769, p. 306 - 312$$p306 - 312$$tEuropean journal of pharmacology$$v769$$x0014-2999$$y2015
000284094 8564_ $$uhttps://pub.dzne.de/record/284094/files/DZNE-2026-00102_Restricted.pdf
000284094 8564_ $$uhttps://pub.dzne.de/record/284094/files/DZNE-2026-00102_Restricted.pdf?subformat=pdfa$$xpdfa
000284094 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001782$$aExternal Institute$$b8$$kExtern
000284094 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000284094 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-13$$wger
000284094 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-13
000284094 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-13
000284094 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-13
000284094 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-13
000284094 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-13
000284094 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-13
000284094 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-13
000284094 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-13
000284094 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-13
000284094 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J PHARMACOL : 2022$$d2024-12-13
000284094 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-13
000284094 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-13
000284094 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J PHARMACOL : 2022$$d2024-12-13
000284094 920__ $$lyes
000284094 980__ $$ajournal
000284094 980__ $$aI:(DE-2719)1040260
000284094 9801_ $$aEXTERN4VITA